Efficiency of carvedilol in the protection of Anthracycline-induced cardiomyophy in cancer patients undergoing chemotheraphy compared with control group

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014121213090N2

Enrollment

Registered

2015-01-09

Start date

2015-01-30

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer. Malignant Neoplasms

Interventions

Intervention 1: In case group,at least 24 hours before chemotherapy,carvedilol 3.12- 6.25mg BID is initiated and continued till termination of chemotherapy. Intervention 2: Control group receive chemo

Treatment - Drugs

In case group,at least 24 hours before chemotherapy,carvedilol 3.12- 6.25mg BID is initiated and continued till termination of chemotherapy.

Control group receive chemotherapy drug alone.

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Cancer patients; 18-70 years old; newly diagnosed; candidate for antracyclin therapy. Exclusion criteria: history of myocardial infarction; coronary artery disease; LVEF<50%; significant valvular heart disease; history of congestive heart failure; sinus bradycardia, complete heart block, systolic blood pressure less than 90 mmHg.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Cardiomyopathy. Timepoint: Before treatment,6 months later. Method of measurement: Echocardiography.	—

Secondary

Measure	Time frame
Level of cardiac Troponin-I. Timepoint: One month after treatment. Method of measurement: Venopuncture.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Nabati

Mazandaran University of Medical Sciences

dr.mr.nabati@gmail.com+98 11 3332 4002

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026